Based on the anti-proliferative activity of AZ304 alone and in combination with Cetuximab in CRC cells in vitro, we next tested whether monotherapy and the combination strategy were effective in vivo by using RKO (BRAF mutant colorectal cancer cell) and Caco-2 (BRAF wild type colorectal cancer cell) xenografts in athymic nude mice. This evidence concerns the gene BRAF and colorectal carcinoma.